Kincell Bio helps innovators swiftly move their cell therapies from concept to IND through structured CMC strategy, DoE-driven process development, and phase-appropriate analytics. We balance speed with full consideration of later phases to build a strong foundation that supports clinical success, investor confidence, and commercial readiness.
Kincell designs CMC strategies with the end in mind. From the earliest IND-enabling work, our teams define the target product profile, assess process and analytical gaps, and build risk-based roadmaps that anticipate BLA expectations. Using DoE-driven development, phase-appropriate analytics, and early process characterization, we strengthen control strategies as programs advance. With integrated GMP manufacturing, validation planning, and PAI readiness built in, our CMC approach evolves deliberately from clinical agility to inspection-ready commercial robustness.
Kincell advances programs toward IND submission through structured stage gates, including process evaluations, establishment runs, and final pilot batches. By aligning Target Product Profile, analytical control strategy, and GMP documentation early, we confirm process performance, assess donor variability, and ensure a seamless transition to clinical manufacturing with regulatory confidence.
We integrate process and analytical development from day one, ensuring meaningful data informs manufacturing decisions. Through DoE-driven optimization, phase-appropriate assay development, and continuous feedback between our labs and GMP suites, teams link critical process parameters to product attributes, accelerating development while strengthening long-term control and commercial readiness.
From the earliest phases of a cell therapy program through commercial supply, our CMC roadmaps guide the development process, reducing risk, improving quality, and accelerating time to market.
Target Product Profiles and risk-based strategies aligned with IND and long-term commercial goals, while applying DoE-driven process optimization and phase-appropriate analytical approaches to strengthen process understanding, improve consistency, and support regulatory readiness as programs advance.
Integrated Services
The Cornerstones of Cell Therapy Excellence, explores analytical, process development, quality, and manufacturing approaches that enable sustainable progress from early development through...
In our new eBook, Navigating Intensifying Cell Therapy Regulatory Expectations, Kincell Bio’s scientific and executive leadership break down what’s changed, why programs...
This webinar explores how integrated PD/AD expertise can deliver robust, regulatory-ready assays and accelerates cell therapy development.
Talk to an expert
Leveraging our science-first expertise and right-first-time quality, partner with Kincell Bio to advance your cell therapy from concept to commercialization.
"*" indicates required fields
